StreetInsider.com News Articles

Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho

Thu, 12 Mar 2026 17:06:39 -0400

Mizuho analyst Uy Ear raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $31.00 (from $26.00) while maintaining a Outperform rating.

The analyst commented, "We update our Sarepta model to incorporate 2026 guidance for product sales and operating expenses and raise our price target to $31 from $26, reiterating our Outperform rating. Our revisions assume steeper Exondys 51 erosion beginning in 2027 due to potential competition from Dyne’s (DYNE, not covered) z‑rostudirsen, but this is offset by our reinstatement of our full valuation for Amondys 45/Vyondys 53. Recent FDA developments suggest improving regulatory flexibility with rare-disease development going forward, which

Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho

Thu, 12 Mar 2026 17:06:39 -0400

Mizuho analyst Uy Ear raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $31.00 (from $26.00) while maintaining a Outperform rating.

Form 144 Sarepta Therapeutics, Filed by: Mayo Stephen

Thu, 12 Mar 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260312/26153631.html

Form 144 Sarepta Therapeutics, Filed by: Mayo Stephen

Thu, 12 Mar 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260312/26153631.html

Form 4 Sarepta Therapeutics, For: Mar 09 Filed by: Wong Ryan Ho-Yan

Wed, 11 Mar 2026 20:08:00 -0400

si-local-file:///var/storage/secattach/20260311/26147733.html

Form 4 Sarepta Therapeutics, For: Mar 09 Filed by: Wong Ryan Ho-Yan

Wed, 11 Mar 2026 20:08:00 -0400

si-local-file:///var/storage/secattach/20260311/26147733.html

Form 4 Sarepta Therapeutics, For: Mar 09 Filed by: Rothfuss Cristin

Wed, 11 Mar 2026 20:07:00 -0400

si-local-file:///var/storage/secattach/20260311/26147732.html

Form 4 Sarepta Therapeutics, For: Mar 09 Filed by: Rothfuss Cristin

Wed, 11 Mar 2026 20:07:00 -0400

si-local-file:///var/storage/secattach/20260311/26147732.html

Form 4 Sarepta Therapeutics, For: Mar 09 Filed by: Rodino-Klapac Louise

Wed, 11 Mar 2026 20:04:00 -0400

si-local-file:///var/storage/secattach/20260311/26147724.html

Form 4 Sarepta Therapeutics, For: Mar 09 Filed by: Rodino-Klapac Louise

Wed, 11 Mar 2026 20:04:00 -0400

si-local-file:///var/storage/secattach/20260311/26147724.html

Form 4 Sarepta Therapeutics, For: Mar 09 Filed by: Estepan Ian Michael

Wed, 11 Mar 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260311/26147721.html

Form 4 Sarepta Therapeutics, For: Mar 09 Filed by: Estepan Ian Michael

Wed, 11 Mar 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260311/26147721.html

Sarepta Therapeutics (SRPT) PT Raised to $9 at Citi

Tue, 10 Mar 2026 06:35:57 -0400

Citi analyst Yigal Nochomovitz raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $9.00 (from $8.00) while maintaining a Sell rating.

Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT) following MDA conference 2026

Mon, 09 Mar 2026 15:22:37 -0400

Jefferies analyst Andrew Tsai reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)

The analyst commented, "At MDA 2026, SRPT shares analyses on: (1) Amondys/Vyondys' confirmatory ESSENCE study in DMD Exon 45/53 that support FDA discussions in March 2026 on a path forward for full approval, (2) Elevidys' long-term benefits in ambulatory DMD, based on 2-3 year Phase III EMBARK data, (3) SRP-9004's Phase Ib data in LGMD2D/R3 (discontinued), including a safety disclosure that could bode well for Elevidys+siroliomus' ENDEAVOR Cohort 8 data in ambulatory DMD by YE:26... New post-hoc analyses on the confirmatory ESSENCE trial (N=228)

Form 4 Sarepta Therapeutics, For: Mar 02 Filed by: Rothfuss Cristin

Tue, 03 Mar 2026 20:07:00 -0400

si-local-file:///var/storage/secattach/20260303/26105342.html

Form 4 Sarepta Therapeutics, For: Mar 02 Filed by: Rothfuss Cristin

Tue, 03 Mar 2026 20:07:00 -0400

si-local-file:///var/storage/secattach/20260303/26105342.html

Form 4 Sarepta Therapeutics, For: Mar 02 Filed by: Wong Ryan Ho-Yan

Tue, 03 Mar 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20260303/26105330.html

Form 4 Sarepta Therapeutics, For: Mar 02 Filed by: Wong Ryan Ho-Yan

Tue, 03 Mar 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20260303/26105330.html

Form 4 Sarepta Therapeutics, For: Mar 01 Filed by: Estepan Ian Michael

Tue, 03 Mar 2026 20:04:00 -0400

si-local-file:///var/storage/secattach/20260303/26105324.html

Form 4 Sarepta Therapeutics, For: Mar 01 Filed by: Estepan Ian Michael

Tue, 03 Mar 2026 20:04:00 -0400

si-local-file:///var/storage/secattach/20260303/26105324.html

Form 4 Sarepta Therapeutics, For: Mar 01 Filed by: Rodino-Klapac Louise

Tue, 03 Mar 2026 20:02:00 -0400

si-local-file:///var/storage/secattach/20260303/26105317.html

Form 4 Sarepta Therapeutics, For: Mar 01 Filed by: Rodino-Klapac Louise

Tue, 03 Mar 2026 20:02:00 -0400

si-local-file:///var/storage/secattach/20260303/26105317.html

Sarepta Therapeutics (SRPT) PT Raised to $25 at Freedom Capital Markets

Tue, 03 Mar 2026 15:44:11 -0400

Freedom Capital Markets analyst Ilya Zubkov raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $25.00 (from $17.00) while maintaining a Buy rating.

The analyst comments "Product revenue continues to decline as ELEVIDYS’ reputation weakened in 2025. The PMO portfolio remains the only revenue support over the next 1–2 years. ● Optimization measures reinforced the outlook for Sarepta to return to positive operating margin starting in 2026. ● The early pipeline provides a basis for cautious optimism regarding viable products beyond DMD. ● Given

Sarepta Therapeutics (SRPT) PT Raised to $25 at Freedom Capital Markets

Tue, 03 Mar 2026 15:44:11 -0400

Freedom Capital Markets analyst Ilya Zubkov raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $25.00 (from $17.00) while maintaining a Buy rating.

Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story"

Tue, 03 Mar 2026 12:00:08 -0400

Jefferies analyst Andrew Tsai reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)

The analyst commented, "SRPT is a pot'l recovery story in 2026: (1) A new Elevidys launch initiative could enable sales to rebound in H2:26 (80% of ambulatory DMD pts are still untreated), (2) In Q1:26, we think initial DM1/FSHD data ($1B+ oppty apiece) could be informative, with more complete MAD data in H2:26 to be certainly conclusive (+25-50% stock move), (3) In Q1:26, mgmt believes an FDA meeting on the next steps for two PMOs (post ESSENSE data) should lead to a (+) outcome.